Harnessing Genetically Engineered Cell Membrane-Derived Vesicles as Biotherapeutics
Author Information
Author(s): Li Xiaohong, Wei Yuting, Zhang Zhirang, Zhang Xudong
Primary Institution: Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Sun Yat-Sen University
Hypothesis
Can genetically engineered cell membrane-derived vesicles (CMVs) be effectively utilized as biotherapeutics for various diseases?
Conclusion
Genetically engineered CMVs show promise as a novel drug delivery system for treating cancer, diabetes, and other diseases.
Supporting Evidence
- CMVs have stable lipid bilayer structures and favorable biocompatibility.
- Genetic engineering can enhance the targeting and therapeutic effects of CMVs.
- Engineered CMVs can deliver drugs and nucleic acids effectively.
- CMVs can be used in treating tumors, diabetes, and autoimmune diseases.
Takeaway
Scientists are using tiny bubbles made from cell membranes to deliver medicine directly to sick cells, which could help treat diseases like cancer and diabetes.
Methodology
The review outlines preparation strategies, characteristics for purifying CMVs, and advances in their use for targeting organs and delivering drugs.
Limitations
Genetically modified CMVs may have issues with packing efficiency and potential damage to donor cell activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website